FDA OKs Abemaciclib for ER+, HER2- Breast Cancer [News in Brief]

The FDA has approved abemaciclib for women with advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy. This is the third CDK4/6 inhibitor to get the agency's go-ahead in 2.5 years.

from Cancer via ola Kala on Inoreader http://ift.tt/2xNICo5
via IFTTT